Enanta Pharmaceuticals News

Enanta Pharmaceuticals(ENTA.US) Officer Sells US$89,589.78 in Common Stock

$Enanta Pharmaceuticals(ENTA.US)$ Officer Kieffer Tara Lynn sold 7,266 shares of common stock on Jun 17, 2024 at an average price of $12.33 for a total value of $89,589.78.Source: Announcement What is

moomoo NewsJun 17 21:19 ET

Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference

PDF Version WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virolog

Enanta PharmaceuticalMay 29 00:00 ET

Express News | Enanta Pharmaceuticals Inc : Evercore ISI Cuts Target Price to $30 From $35

ReutersMay 9 11:26 ET

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shareholders are probably feeling a little disappointed, since its shares fell 8.3% to US$12.76 in the week after its latest quarterly results. Revenue

Simply Wall StMay 9 07:41 ET

Enanta Pharmaceuticals | 10-Q: Quarterly report

SEC announcementMay 8 16:04 ET · Announcements

Hold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial Outlook

TipRanksMay 7 23:58 ET

Enanta Pharmaceuticals Is Maintained at Market Outperform by JMP Securities

Enanta Pharmaceuticals Is Maintained at Market Outperform by JMP Securities

Dow JonesMay 7 11:44 ET

Buy Rating Affirmed for Enanta Pharmaceuticals Amidst Promising RSV Developments and Clinical Trial Execution

TipRanksMay 7 11:35 ET

Express News | JMP Securities Maintains Market Outperform on Enanta Pharma, Lowers Price Target to $22

BenzingaMay 7 11:34 ET

Enanta Pharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 67.81% JMP Securities $23 → $22 Maintains Market Outperform 02/08/2024 -16.09% JP Morgan $12 →

BenzingaMay 7 11:32 ET

Express News | Enanta Pharmaceuticals Inc : H.c. Wainwright Cuts Target Price to $27 From $28

ReutersMay 7 11:22 ET

NanoViricides, TC BioPharm, Holdco Nuvo Among Healthcare Movers

Seeking AlphaMay 7 10:01 ET

Express News | Enanta Pharmaceuticals Inc : Oppenheimer Cuts Target Price to $16 From $17

ReutersMay 7 07:24 ET

Earnings Call Summary | Enanta Pharmaceuticals(ENTA.US) Q2 2024 Earnings Conference

The following is a summary of the Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript:Financial Performance:Enanta reported total Q2 revenue of $17.1 million from royalty revenue on A

moomoo AIMay 7 05:26 ET · Conference Call

Analysts' Opinions Are Mixed on These Healthcare Stocks: Enanta Pharmaceuticals (ENTA), OrthoPediatrics (KIDS) and Avanos Medical (AVNS)

TipRanksMay 7 00:51 ET

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference

PDF Version WATERTOWN, Mass.--(BUSINESS WIRE)--May 7, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology

Enanta PharmaceuticalMay 7 00:00 ET

Express News | Enanta Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $12 From $13

ReutersMay 6 23:27 ET

Express News | Enanta Pharmaceuticals Inc: Qtrly Shr Loss $1.47

ReutersMay 6 16:42 ET

Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q2 Revenue $17.1M, Vs. Street Est of $16.2M

04:04 PM EDT, 05/06/2024 (MT Newswires) -- Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q2 Revenue $17.1M, vs. Street Est of $16.2M

MT NewswiresMay 6 16:04 ET

Express News | Enanta Pharmaceuticals Q2 Net Income USD -31.157 Million Vs. Ibes Estimate USD -28 Million

ReutersMay 6 16:01 ET